A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint inhibitors experience increased susceptibility to common infections.
PD-1 deficiency reveals the impact of checkpoint inhibition on B cell function
- Post author:
- Post published:November 27, 2024
- Post category:uncategorized